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Background: Hepatitis C virus (HCV) is a major cause of chronic liver dis-
ease, including cirrhosis and liver cancer. The aim of our study was to deter-
mine whether IL28B single nucleotide polymorphisms (SNPs) rs12979860 and 
rs8099917 can be considered a prognostic host factor in untreated chronic 
HCV patients. Methods: We set up a real-time Allele Specific PCR amplifica-
tion to determine the allele present in each polymorphic site, and statistically 
grouped and compared this result with clinical data. Results: We determined 
rs12979860 and rs8099917 genotype and allele frequencies in a single cohort 
of untreated chronically HCV-infected patients. We found significant associa-
tions between higher inflammatory activity, measured as ALT levels or 
METAVIR scores and rs12979860 CC (P = 0.0013 and P = 0.0033, respective-
ly) and rs8099917 TT (P = 0.0005 and P = 0.0264, respectively) genotypes. In-
terestingly, considering both genotypes together, we also found association 
with ALT levels (P = 0.0003; OR = 5.125) or METAVIR scores (P = 0.0038; 
OR = 5.179), suggesting and additive effect on liver inflammation in these pa-
tients. Conclusion: we show association between hepatic inflammatory activ-
ity in a single Argentinean untreated chronically HCV cohort and SNPs lo-
cated in the interferon lambda gene region. The studied polymorphisms, to-
gether with further innate and adaptive immune responses, clearly play a role 
in modulating the HCV infected patients outcome, contributing to hepatic in-
flammation and possible fibrosis/cirrhosis. 
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Chronic hepatitis C is a liver disease caused by the hepatitis C virus (HCV), a 
blood-borne virus mostly transmitted through unsafe injection practices, but al-
so from inadequate sterilization of medical equipment, or unscreened blood and 
blood products. HCV can cause both, self limited and chronic infections, rang-
ing in severity from a mild, few weeks lasting illness, to a serious, lifelong illness. 
Based on World Health Organization reports, 150 million people are infected 
with chronic hepatitis C (approximately 600,000 in Argentine), and around 
500,000 people die each year from hepatitis C-related liver diseases [1]. Unfor-
tunately a vaccine for hepatitis C is not currently available. Early diagnosis of the 
HCV infection is rare. Those people who go on to develop chronic HCV infec-
tion remain undiagnosed, often until serious liver damage has developed. Al-
though many direct acting antivirals have been developed in recent years, these 
are not widely available. The most widespread standard treatment at the mo-
ment is interferon alpha plus ribavirin. The success of such therapy depends on 
host and virus factors [2]. The degree of liver damage, measured by liver biopsies 
or through a variety of non-invasive tests, together with the determination of 
HCV genotype, is used to guide therapeutic decisions and management of the 
disease, to determine the most appropriate approach for each patient. In order to 
contribute to decisions related to the course of treatment, several groups work-
ing in Genome Wide Association Studies identified Single Nucleotide Polymor-
phisms (SNPs) associated to the outcome of antiviral therapy in chronic HCV 
patients [3] [4] [5] [6] [7]. Among them the SNPs rs12979860 and rs8099917 
showed the most significant statistical relevance. These SNPs that were also as-
sociated with spontaneous virus clearance in acute infection [8] [9] [10], and 
appeared to modify the natural course of disease [11], are located close to the 
IL28B locus, containing a gene coding for interferon lambda 3 (IFN-λ3) that be-
longs to the type III interferon-family [12]. However, it is unclear how these 
SNPs affect transcription or protein expression. Regarding IFN-λs, these are 
known to be able to inhibit virus replication [13] [14], including HCV [15], and 
share with type I interferon a similar anti-viral effect. The role of these SNPs in 
the host inflammatory response and evolution of chronic infection in untreated 
chronic HCV patients is not well understood. Recent studies yielded contradic-
tory results and have shown rs12979860 CC (or rs8099917 TT) association with 
more advanced fibrosis or cirrhosis [16] [17] and worse clinical outcomes [18], 
while others have reported rs12979860 TT (or rs8099917 GG) to be associated 
with more advanced fibrosis or cirrhosis [19] [20] [21] or even no association of 
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IL28B genotype with fibrosis [22]. The aim of our study was to determine whether 
SNPs rs12979860 and rs8099917 can be considered a prognostic host factor in un-
treated chronically HCV-infected patients from an Argentine cohort, by analyzing 
host haplotypes involved in modulation of patient’s immune responses. 
2. Materials and Methods 
2.1. Study Design 
The study was designed and performed (years 2015-2017) using samples stocked 
during routine medical practice. The study has been approved by the Research 
and Ethics Committee at both involved centers and performed in accordance 
with the ethical standards adopted in the Declaration of Helsinki and revised 
forms. Informed consent was obtained from all donors. 
2.2. Subjects 
Samples from 150 HCV chronically infected patients were included. All individ-
uals were aged ≥ 18 years, and patients were not undergoing any kind of HCV 
antiviral therapy. Exclusion criteria included alcohol intake greater than 20 g 
day−1, history of organ transplantation, creatinine clearance < 50 mL min−1, 
co-infection with hepatitis B virus or human immunodeficiency virus and African 
American or Asian ethnicity. Patients were also excluded if they presented evi-
dence of other liver disease, such as autoimmune hepatitis, primary biliary cholan-
gitis, sclerosing cholangitis, Wilson’s disease or alpha-1-antitrypsin deficiency. 
2.3. Genotype Determination 
Genomic DNA was obtained from blood samples using the standard method of 
phenol:chloroform extraction. Genotypes were determined by allele specific am-
plification on a real-time PCR detection system (Mx3000P, Stratagene) using SYBR 
Green as fluorescent DNA binding dye, complementary primer sets in separate 
tubes, and Taq Platinum polymerase (Invitrogen).  
Primers sequences were:  
rs12979860: 
Forward: 5’-CGCTTATCGCATACGGCTAG-3’,  
Reverse C: 5’-GCAATTCAACCCTGGTTCGC-3’, 
Reverse T: 5’-GCAATTCAACCCTGGTTCAC-3’. 
rs8099917: 
Forward: 5’-CCTCATCCCACTTCTGGAAC-3’, 
Reverse T: 5’-CATGGTTCCAATTTGGGTGAAA-3’, 
Reverse G: 5’-CATGGTTCCAATTTGGGTGACA-3’. 
Primer sets yielded a single product of the correct size with their specific DNA 
templates and no or extremely retarded amplification with the unspecific alleles. 
2.4. Histological Parameters 
Liver biopsies were obtained from patients, simultaneously with peripheral blood 
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samples, and before any treatment against HCV infection. Tissue was fixed in 
formaldehyde (10%) and included in paraffin. After Masson’s trichromic stain, 
inflammatory activity was determined by microscopic analysis attributing 
METAVIR scores for each patient based on histopathologic features [23]. Pa-
tients being attributed METAVIR scores A2 or A3 were considered as having a 
high inflammatory activity. This activity was also measured indirectly by Alanine 
aminotransferase (ALT) determination in blood samples, considering as high 
those values over twice the normal value (N, men: 41 UI mL−1, women: 31 UI 
mL−1). Patients being attributed METAVIR scores F3 and F4 were considered as 
presenting advanced fibrosis. For those patients without liver biopsies, ultrasonic 
transient elastography (Fibroscan 502) study was performed, considering scores 
F3 and F4 as indicator of advanced fibrosis. 
2.5. Statistics 
Association between liver inflammatory activity and SNPs was studied with 
Fisher exact and Chi square tests. Analysis was performed with GraphPad Prism 
3.0 (GraphPad Software). P values were considered significant when lower than 
0.05. Odds ratios (OR) were determined using the following formula: OR = 
AxD/BxC, being A the number of patients harboring the studied allele and B the 
number of patients not harboring the studied allele, both with high inflammato-
ry activity, C, the number of patients harboring the studied allele and D the 
number of patients not harboring the studied allele, both with low inflammatory 
activity. 
3. Results 
3.1. Clinical Features of Patients 
A total of 150 untreated chronic HCV-infected patients were included. Clinical 
features are summarized in Table 1. Sixty-two percent were males, with a mean 
age of 48.9 ± 9.8 years (range 19 - 76 years old). The date of infection could be 
estimated for 37 patients (25%) being the use of unsafe injections the main in-
fection route (34 patients, 23%). Viral genotype was established for 135 patients. 
Most of them were infected with genotype 1 (n = 93, 62%), where genotype 1a 
was found in 43 patients, and genotype 1b in 30 patients. Viral load (n = 113) 
ranged from 1978 IU mL−1 to 30,800,000 IU mL−1 (Mean: 1,668,031.79 ± 
2,657,526.68 IU mL−1), Serum ALT levels were determined in 137 patients, ob-
taining normal values in 71 patients (47%). Hepatic biopsies were available for 
91 patients. Among them, 38 patients presented a METAVIR score A2 - A3, 
considered as advanced inflammatory activity. Fibrosis level was determined in 
136 patients, and an advanced level of fibrosis was detected in 49 of them (33%). 
3.2. rs12979860 and rs8099917 
For rs12979860 the most frequent allele presented a base C at the polymorphic 
position (60%), being the heterozygous CT genotype the most frequent (45%).  
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Table 1. Clinical features of patients. 
Mean age 48.9 ± 9.8 years 
Gender 62% men/38% women 
rs8099917 TT genotype 42% 
rs12979860 CC genotype 38% 
Cause of infection: 
 
Transfusions 2% 
Unsafe injections 23% 
Unknown 75% 
HCV genotype 1 62% 
Mean HCV RNA 1,668,031 ± 2,657,526 IU/mL 
Elevated ALT (>2xN) 44% 
Biopsy A2 - A3 25% 
Metavir F3 - F4 score 33% 
 
Table 2. Genotypes and alleles representation in samples (a) and distribution of coinci-





CC 38% TT 42% 
CT 45% TG 42% 
TT 17% GG 16% 
Allele: 
C 60% T 63% 
T 40% G 37% 
(b) 
rs12979860 rs8099917 n 
C T 136 
C G 18 
T T 25 
T G 75 
 
For rs8099917, allele T was the most represented in samples (63%). Both TT and 
TG genotypes were equally represented (42%), (Table 2(a)). Alleles C (rs12979860) 
and T (rs8099917) were coincident in 88% of cases, whereas alleles T (rs12979860) 
and G (rs8099917) were present together in 75% of cases (Table 2(b)). 
3.3. SNPs rs12979860 and rs8099917 and Inflammatory Activity 
The ALT levels were abnormal in 67% of HCV patients harboring rs12979860 
genotype CC, whereas this was observed in only 38% of non-CC patients (P = 
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0.0013; OR = 3.200; Figure 1(a)). This association was also found when the 








Figure 1. Association of rs12979860 and inflammatory activity. SNP rs12979860 is asso-
ciated with higher ALT levels in CC compared to no-CC patients, independently of HCV 
genotype (a) or considering only HCV genotype 1 (b). Similar association is found when 
using METAVIR score as inflammation indicator (c). Data were analyzed by Chi square test. 
n, P and odd ratios (OR) are indicated in each panel. Asterisks denote significance level. 
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CC individuals showed high ALT levels in contrast to 39% of non-CC individu-
als (P = 0.0027; OR = 4.750; Figure 1(b)), and when considering genotypes 1a 
and 1b independently (P = 0.039, P = 0.044, respectively, data not shown). Using 
METAVIR score, a direct measure of inflammatory activity, 62% of CC patients 
showed a high score (A2 - A3) in comparison with 31% of non-CC individuals 
(P = 0.0033; OR = 3.801; Figure 1(c)). On the other hand, 65% of HCV patients 
harboring rs8099917 genotype TT presented high ALT levels, in contrast to 32% 
of non-TT individuals (P = 0.0005; OR = 3.896; Figure 2(a)), and this associa-
tion was also found when we analyzed separately HCV genotype 1 infected pa-
tients (P = 0.03, data not shown). Analyzing METAVIR scores, 57% of TT pa-
tients presented a high score (A2 - A3) compared to 31% of non-TT individuals 
(P = 0.0264; OR = 2.877; Figure 2(c)). When analysis was performed consider-
ing rs8099917 genotype GG versus non-GG, only 26% of rs8099917 GG patients 
showed high ALT levels, in contrast to 49% of non-GG individuals (P = 0.0693; 
OR = 0.3720; Figure 2(b)). Association was found when using METAVIR scores 
for comparison: 91% of rs8099917 GG individual had lower inflammatory ac-
tivity compared to 46% of non-GG patients (P = 0.0202; OR = 8.611; Figure 







DOI: 10.4236/ijcm.2018.92009 85 International Journal of Clinical Medicine 
 






Figure 2. Association of rs8099917 and inflammatory activity. SNP rs8099917 is asso-
ciated with higher ALT levels in TT patients (a), but not when comparing GG vs no-GG 
patients (b). When using METAVIR score as inflammation indicator, statistically signifi-
cant association was found in both comparisons, TT vs no-TT (c), and GG vs no-GG (d). 
Data were analyzed by Fisher exact test. n, P and odd ratios (OR) are indicated in each 
panel. Asterisks denote significance level. 
 
genotypes and higher ALT levels, we analyzed the possible association of both 
polymorphisms together. 71% of HCV patients harboring genotypes CC and TT 
(rs12979860 and rs8099917, respectively) showed high ALT levels, in contrast to 
33% of non-CC/non-TT individuals (P = 0.0003; OR = 5.125, Figure 3(a)). 
When using METAVIR scores for comparison, 68% of CC/TT patients showed 
higher inflammatory activity compared to 29% of non-CC/non-TT patients (P = 
0.0038; OR = 5.179; Figure 3(b)). Finally, to explore whether these relationships 
between studied SNPs and increased inflammatory activity could be confounded 
by HCV RNA levels, we compared viral load in the different rs12979860 and 
rs8099917 genotypes. No association was found.  
In summary, SNPs rs12979860 and rs8099917 are associated with higher in-
flammatory activity as measured by alanine transaminase (ALT) levels and  
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Figure 3. Association of CC (rs12979860) and TT (rs8099917) genotypes and high in-
flammatory activity. Genotypes CC (rs12979860) and TT (rs8099917) are associated with 
high inflammatory activity as measured by ALT levels. Data were analyzed by Chi square 
test (a) and Fisher exact test (b). n, P and odd ratio (OR) are indicated in the panel. Aste-
risks denote significance level. 
 
METAVIR score. 
3.4. rs12979860 and rs8099917 and Fibrosis 
As a high liver inflammatory activity can lead to fibrosis/cirrhosis, we analyzed 
the association of specific patient alleles with advanced fibrosis scores (F3 - F4). 
The rs12979860 CC genotype was present in 33% of patients with early stage fi-
brosis, compared to 45% of patients with advanced fibrosis, a difference that was 
not statistically significant. Similar result was obtained when analyzing rs8099917 
genotypes: 34% of patients harboring rs8099917 TT genotype presented early stage 
fibrosis, compared to 48% of patients with advanced fibrosis (Data not shown). 
These results suggest that SNPs are not significantly associated with fibrosis. 
4. Discussion 
HCV faces, during chronic infection, complex mechanisms of host innate and 
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adaptive immunity. As previously mentioned, host genetics plays an important 
role in the outcome of antiviral therapy [3] [4] [5] [6] [7]. We found that C and 
T were the most represented alleles for rs12979860 and rs8099917, respectively. 
Considering the possible genotypes, we found that CT was the most represented 
for rs12979860 and TT and TG for rs8099917. C/T and T/G alleles (rs12979860/ 
rs8099917) were found together in approximately 85% of individuals, suggesting 
a strong linkage and inheritance as a haplotype, as has been previously reported 
[3]. However, the allele frequency of rs8099917 differs between populations 
worldwide, so this linkage may vary between diverse cohorts [24]. A study car-
ried out in a Spanish cohort showed similar results for rs12979860 allele C fre-
quency [8]. Our results are consistent with a previous report [7] in Argentine 
patients of European ancestry, and to our knowledge, the first report with such a 
genetic analysis on a single Latin-American cohort in untreated HCV-infected 
patients. Furthermore, we show for the first time an association between hepatic 
inflammatory activity in a single Argentine cohort of untreated chronically 
HCV-infected patients and single nucleotide polymorphisms located close to 
IFN-λ3. The association we described here was neither dependent on HCV ge-
notype nor confounded by viral load. The immune response to HCV infection is 
established and modulated by liver-infiltrated immune cells [25]. The hepatic in-
flammatory activity is a clinically useful tool to follow such response, through 
the measurement of ALT levels as well as through the analysis of liver biopsies. 
In the untreated chronically HCV infected patients we found a statistically sig-
nificant association between a higher inflammatory activity grade and the 
rs12979860 CC genotype. Previous studies have shown that this genotype was 
also associated with a better response to pegylated interferon-alpha and ribavirin 
treatment [3] [4] [5] [6] [7] [9] [12] and with spontaneous virus clearance [9]. In 
our group of untreated patients we found a significant association with a higher 
inflammatory activity grade for the rs8099917 TT genotype. Further, considering 
both genotypes together (rs12979860 CC and rs8099917 TT), we also found this 
association to be significant, suggesting and additive effect on liver inflammation 
in patients harboring both genotypes. As these polymorphisms are close to 
IFN-λ3, which has been involved in the modulation of antiviral responses [13] 
[26] [27] [28], our results, in agreement with a recent report concluding that 
IFN-λ3 rather than IFN-λ4 likely mediates haplotype-dependent hepatic in-
flammation and fibrosis [29], support the hypothesis that this interferon is con-
tributing to a stronger immune response to HCV during the acute infection 
phase, favoring the spontaneous clearance. Moreover, they also suggest a role for 
this cytokine in the chronic infection inducing a favorable outcome to the anti-
viral therapy. For those untreated patients who entered into a chronic phase the 
presence of these genotypes clearly favor an inflammatory liver state. While oth-
er groups have reported similar findings [11] [18], our study further confirm 
and extend the knowledge on the field through the analysis of a single cohort re-
cruited in a specialized unit where all parameters were evaluated by a single pan-
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el of experts, limiting the effects of sampling errors, and with simple clinical 
tools routinely used in public health facilities from poor countries. Hepatic in-
flammatory activity can lead, on time, to the appearance of fibrosis and lately to 
cirrhosis. When we analyzed the fibrotic liver stage in patients, we found that 
rs12979860 CC and rs8099917 TT genotypes were not significantly associated 
with advanced fibrosis, albeit they were more represented at these stages. This 
was in agreement with previous studies [18] [22], but opposed to other results 
reporting an association either for the major genotypes [16] [17] or the minor 
ones (rs12979860 TT and rs8099917 GG) [19] [20] [21]. There might be multiple 
reasons contributing to such conflicting results, including study design, sample 
size, known (i.e. infection lasting) and unknown mechanisms contributing to fi-
brosis progression, etc. Further studies on chronically untreated HCV-infected 
patients with known time from infection are required to elucidate whether the 
studied polymorphisms can contribute to fibrosis/cirrhosis through a prolonged 
inflammatory context. A full understanding of the implications of harboring 
specific rs12979860 and rs8099917 genotypes will require considerably larger pa-
tient group size, that would allow individual analysis considering other factors 
(like alcohol consumption, gender, age, body mass index, etc.) influencing the 
immune response to HCV. The applicability of our findings for the actual direct- 
acting antiviral therapies, where there are no data available on long term clinical 
effects, mainly in terms of chronic infection and inflammation, has to be dem-
onstrated in future studies. Our study adds a piece of knowledge to the implica-
tions of genetic polymorphisms in the evolution of untreated chronic HCV in-
fection. The studied polymorphisms, together with further innate and adaptive 
immune responses, clearly play a role in modulating the HCV infected patient 
outcome. In some of such patients, rs12979860 CC and rs8099917 TT genotypes 
will contribute to a spontaneous or treatment-induced clearance of the virus. In 
other cases, particularly on those that will develop chronic infection, the same ge-
notypes will contribute to hepatic inflammation and possibly fibrosis/cirrhosis. 
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